Anavex Life Sciences Corp. AVXL 深 沪
已收盘 05-15 16:00:00 美东时间
2.91
-0.170
-5.52%
华盛通- 最 高3.06
- 今 开3.04
- 成交量 121.65万股
- 最 低 2.885
- 昨 收 3.08
- 总市值 2.70亿
- 52周最高 13.99
- 市盈率 静 --
- 换手率 1.31%
- 52周最低 2.61
- 委 比 84.27%
- 总股本 9267.18万
- 历史最高 31.50
- 量 比 1.10
- 振 幅 5.68%
- 历史最低 0.60
- 每 手 1
- 风险率 2.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Anavex Life Sciences Announces COO Departure Amid Restructuring
Anavex Life Sciences ( ($AVXL) ) has provided an announcement. On May 11, 2026,...
05-16 06:01
Anavex Delays Quarterly Filing Amid CEO Shake-Up
Anavex Life Sciences ( ($AVXL) ) has released a notification of late filing. An...
05-12 07:19
Anavex slips after CEO transition
Shares of Anavex Life Sciences (AVXL) fell ~3% on Wednesday after the Alzheimer’s drug developer named its former R&D head, Terrie Kellmeyer, as its interim chief executive following the departure of ...
05-06 22:29
Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
Anavex Life Sciences Corp. announced that Terrie Kellmeyer, PhD, has been appointed as Interim Chief Executive Officer following the departure of Christopher Missling, PhD, MS, MBA. Dr. Kellmeyer, a seasoned pharmaceutical executive with nearly three decades of experience, will lead the company's next phase of growth, focusing on advancing its clinical development programs, including its lead candidate, oral blarcamesine, for early Alzheimer’s di...
05-06 11:00
Anavex Life Sciences Announces New Findings On The Shared Biology Between Autism Spectrum Disorder And Alzheimer's Disease
Multiple peer-reviewed publications point to biological link between autism spectrum disorder (ASD) and Alzheimer's disease (AD), including shared disruptions in autophagy.Epidemiological data show that autistic adults
04-14 19:34
Anavex Life Sciences to present at Needham Virtual Healthcare Conference
Anavex Life Sciences to present at Needham Virtual Healthcare Conference Anavex Life Sciences will present at Needham 25th Annual Virtual Healthcare Conference, scheduled for April 14, 2026 at 1:30 p.m. ET. Conference runs April 13-16, 2026. Disclaimer: This news brief was created by Public Technolo
04-07 19:32
BUZZ-U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta
BUZZ-U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 25 (Reuters) - Wall Street's main indexes were set to open higher on W
03-25 21:29
Anavex drops after pulling EU marketing application for Alzheimer’s therapy
Anavex Life Sciences (AVXL) lost ~18% in the premarket on Wednesday after the company announced that it withdrew the marketing authorization application for its Alzheimer’s candidate, blarcamesine, in...
03-25 19:57
Anavex Withdraws EU Filing For Alzheimer's Treatment After Regulator Feedback
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia,
03-25 19:34
Anavex Life Sciences withdraws EU marketing authorization application for blarcamesine; EMA CHMP feedback drops chances of a positive opinion
Anavex Life Sciences withdraws EU marketing authorization application for blarcamesine; EMA CHMP feedback drops chances of a positive opinion Anavex Life Sciences withdrew its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzhei
03-25 19:29
